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Adaptation of the Rao-Wu rescaling bootstrap for seroprevalence estimation 





The coronavirus 2019 (COVID-19) pandemic has highlighted a need for accurate seroprevalence 
estimators in order to monitor virus transmission and mortality rates. Furthermore, seroprevalence 
data is used to inform public health policy. Adjustments for diagnostic test sensitivity and 
specificity in seroprevalence estimation are complicated by concerns regarding proper confidence 
interval (CI) coverage and width given that the proportion of a population considered seropositive 
may be relatively small. As such, these methods are not widely implemented at present, 
particularly for complex survey studies. This paper presents a two-stage, non-parametric bootstrap 
method, adapted from the Rao-Wu rescaling bootstrap, for adjusted CI construction. Simulation 
of a stratified, multi-stage cluster sample was conducted to assess the performance of the proposed 
method as measured by empirical bias, 95% CI coverage, and CI width. Across 500 simulations, 
the mean empirical bias was 0.0008 (range, -0.0411–0.0348), the CI empirical coverage was 
95.6%, and CI width was 0.0487. Further application of the proposed method to preliminary study 
data from a Chatham County, North Carolina seroprevalence study demonstrated directionally 
appropriate adjustments for the diagnostic test sensitivity and specificity. The proposed method, 
paired with the Rogan-Gladen estimator for true prevalence, will allow for sensitivity-specificity 
adjusted seroprevalence estimation in complex survey designs while minimizing the CI width and 





COVID-19, the viral disease caused by the novel SARS-CoV-2, was declared a pandemic by the 
World Health Organization (WHO) on March 11, 2020 following alarming levels of global spread 
and severity.1 Following the regulatory approval of seroprevalence assays for SARS-CoV-2 
antibodies, seroprevalence studies have emerged as a key means for surveillance.2 Accurate 
seroprevalence estimates are necessary for modeling virus transmission and determining mortality 
rates, which in turn guide public health policies surrounding COVID-19.2 The demand for rapid 
implementation and data turnaround from these studies, however, has revealed several key issues 
related to data reporting and generalizability of results. 
  
The quality of seroprevalence studies conducted to date has varied greatly. While many studies 
report clear, detailed explanations of the methods used in analysis, some published reports of 
studies provide incomplete information about the study design.3 Missing information makes it 
difficult to assess the quality of the estimates from such studies. A number of seroprevalence 
studies to date have been based on convenience samples recruited from clinics, social media 
platforms, and shopping centers.4–6 Convenience samples are appealing because they are relatively 
inexpensive and can be acquired quickly. Selection bias, however, is often inherent in convenience 
samples due to a wide range of factors that may influence participation, which may limit 
generalizability of results to the total population.2 Probability-based survey sampling techniques 
are based on random selection within a population while allowing quantification of a participant’s 
chance of selection.2 As a result, well-designed probability samples allow for design-based 
representative estimates of the target population. 
  
Other issues arise from the nature of the diagnostic tools used in seroprevalence studies. The 
primary aim of a seroprevalence study is to estimate the proportion of a population that is carrying 
antibodies for a specific infection. An individual’s antibody status is determined using a diagnostic 
test, typically a chemiluminescent immunoassay (CLIA) or enzyme-linked immunosorbent assay 
(ELISA). While antibodies tend to be highly specific in nature, no diagnostic test is perfect, which 
introduces an associated measurement error.7 Disregarding a test’s sensitivity, or the probability 
of a positive result when applied to a known positive, and specificity, or the probability of a 
negative result when applied to a known negative, can lead to biased estimates.8 Seroprevalence 
estimates should be adjusted to account for sensitivity and specificity of the diagnostic test. 
  
Rogan and Gladen9 have proposed a prevalence estimator for known sensitivity and specificity. 
Sensitivity and specificity, however, are often not known quantities but also experimentally-
determined estimates.7 Biggs et al.10 notes serological assay error as an important study limitation. 
While some Bayesian and bootstrap techniques have been developed to adjust for the uncertainty 
in these measures, they have not been widely implemented. Furthermore, there is a lack of 
sensitivity-specificity adjustment methods developed specifically for complex survey designs. 
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Finally, estimating seroprevalence is challenging because at the beginning of the pandemic, overall 
prevalence of SARS-CoV-2 antibodies tended to be low in most populations, leading to estimates 
close to 0.8 In general, confidence limits are more informative than single point estimates because 
they help quantify the uncertainty associated with the estimate. Several concerns arise when 
constructing confidence limits for small proportions11: 
  
Coverage. (1 - α)% coverage is ideal for a (1 - α)% confidence interval (CI). It is consistent 
with current practice to say that for a 95% CI, approximately 95% of similarly computed CIs 
are expected to contain the parameter, or true population value. For example, a 95% CI with 
true coverage of 99% is considered too conservative, while one that covers 90% is considered 
anti-conservative. 
  
CI Width. Provided that the ideal coverage is met, a CI should be narrow in order to be as 
informative as possible. 
  
Aberrations. Anomalies, including CIs of width zero and confidence limits less than 0 or 
greater than 1 for a proportion may be observed. In particular, the standard Wald CI, which is 
based on a normal approximation, can undercover the true proportion.8 
  
A common approach for small proportions is to use the logit transformation of the proportion to 
compute a CI since it ensures that the CI will fall in the [0,1] range.12 There are also alternatives 
to the standard Wald-typed methods, which all use the continuous normal distribution to 
approximate the binomial distribution. The Clopper-Pearson CI, also known as the Exact CI, is 
based on an exact binomial distribution with a lower bound of 0 and upper bound of 1. It is 
considered to produce nominal coverage and tighter confidence intervals,11 performing 
exceedingly well for small proportions when intracluster correlation is high.13 However, it can be 
unnecessarily conservative.11 The Wilson CI cannot produce a negative lower limit and is 
especially recommended for small proportions, although it may not be conservative enough.11,13 
  
An alternative method for constructing CIs is the use of bootstrap techniques. The Rao-Wu 
rescaling bootstrap does not rely on any parametric assumptions, including large sample normality, 
to construct confidence intervals.14 Instead, repeated replicate sampling is used to construct a 
distribution of estimates that captures uncertainty. The CIs are derived from this distribution. As a 
result, the Rao-Wu bootstrap can be specifically applied where small sample size and/or 
fundamentally irregular distributions lead to asymmetric sampling distributions.14 Havers et al.4 
utilized a bootstrap method to account for sensitivity-specificity adjustments and construct CIs for 
seroprevalence estimates based on a convenience sample. The Rao-Wu bootstrap is promising for 
use with complex survey designs due to its ability to accommodate complex sample design 
features, including sampling weights, stratification, and clustering; and its ability to handle small 
sample sizes.15 
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The aim of this paper is to develop, evaluate, and apply a bootstrap method for seroprevalence CI 
construction that (1) can be used for complex survey designs, (2) adjusts for sensitivity-specificity 






Assume that the true population seroprevalence (𝑝) will be estimated based on the results of a 
diagnostic test conducted on a sample of participants from a stratified, multi-stage cluster sample. 
In this design, primary sampling units (PSUs), or clusters of observational units, are stratified. A 
random sample of PSUs is then selected, and units are subsequently randomly selected within 
sampled PSUs. Stratified designs allow the sampling frame to be divided into mutually exclusive 
and exhaustive categories, such as high- or low-risk groups. Sampling may then be used to over-
select from certain strata as necessary. For example, oversampling could be used to give high-risk 
individuals a greater probability of selection compared to low-risk individuals. Sample weights are 
then applied to adjust the seroprevalence estimate appropriately for the sampling strategy 
used. Further, clustered sampling is often used to reduce costs and improved logistic feasibility of 
in-person data collection. 
 
We derive point estimates and confidence intervals in three stages to account for increasing 
complexity in the sensitivity and specificity adjustments. 
 
Stage 1: No measurement error. First, we assume that sensitivity and specificity of the 
diagnostic test were both 100%, i.e., that there was no error in the diagnostic test. We calculate 
seroprevalence population estimates (?̂?) using the ratio estimator common in survey sampling 
(Equation 1).14 (p. 160) This method utilizes the binary classification from the assay 𝑦𝑖 (𝑦𝑖 = 1 
indicates that individual 𝑖 tested positive for antibodies, 𝑦𝑖 = 0 otherwise) and sample weights 









    (Equation 1) 
 
We consider two possible confidence intervals in Stage 1. The Wald CI is presented in 




𝑆?̂?(?̂?)     (Equation 2) 
𝑊ℎ𝑒𝑟𝑒 𝛼 𝑖𝑠 𝑡ℎ𝑒 𝑑𝑒𝑠𝑖𝑟𝑒𝑑 𝑠𝑖𝑔𝑛𝑖𝑓𝑖𝑐𝑎𝑛𝑐𝑒 𝑙𝑒𝑣𝑒𝑙 𝑎𝑛𝑑 𝑆?̂?(?̂?) 𝑖𝑠 𝑡ℎ𝑒 𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑒𝑟𝑟𝑜𝑟 𝑜𝑓 ?̂?. 
 
Note that 𝑆?̂?(?̂?) is estimated using design-consistent estimation methods in software such as 
SAS ‘survey’ procedures, the R ‘survey’ package, or SUDAAN. To produce a CI using the 
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logit of ?̂?, ?̂?, we first apply the logit transformation as shown in Equation 3.12 We then calculate 
a Wald CI for ?̂?. The upper and lower limits of the CI,  ?̂?𝑢𝑝𝑝𝑒𝑟  and ?̂?𝑙𝑜𝑤𝑒𝑟, respectively, are 
then transformed back to the domain of 𝑝 using an inverse-logit transformation (Equations 4 
and 5). 
 
?̂? = log (?̂?/(1 − ?̂?))     (Equation 3) 
𝐿𝐿: 1/(1 + exp(−?̂?𝑙𝑜𝑤𝑒𝑟))    (Equation 4) 
𝑈𝐿: 1/(1 + exp(−?̂?𝑢𝑝𝑝𝑒𝑟))    (Equation 5)  
 
Stage 2: Adjustment for known sensitivity and specificity. We next assume that the 
sensitivity and/or specificity of the diagnostic test is less than 100%, but that they are fixed, 
known quantities. For this scenario, we use the estimator proposed by Rogan and Gladen9 to 
estimate the population seroprevalence (Equation 6) and its estimated standard error (Equation 
7). Confidence intervals in this stage are computed using the formulas from Stage 1, 









   (Equation 7) 
 
𝑊ℎ𝑒𝑟𝑒 𝑠𝑝𝑒𝑐 𝑖𝑠 𝑡ℎ𝑒 𝑘𝑛𝑜𝑤𝑛 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 𝑎𝑛𝑑 𝑠𝑒𝑛𝑠 𝑖𝑠 𝑡ℎ𝑒 𝑘𝑛𝑜𝑤𝑛 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑡𝑖𝑐 𝑡𝑒𝑠𝑡. 
 
Stage 3: Adjustment for estimated sensitivity and specificity. In the final stage, values for 
sensitivity and specificity of the diagnostic test are considered to be laboratory estimates with 
associated variability. As in Stage 2, we use the Rogan-Gladen estimator (?̂?′) to calculate 
seroprevalence point estimates (Equation 6). However, treating the estimated sensitivity and 
specificity as known when estimating variance, as in Equation 7, is anti-conservative. To create 
confidence intervals around our estimates that appropriately account for the estimated 
sensitivity and specificity, we use a two-stage non-parametric bootstrap, based off the Rao-Wu 
rescaling bootstrap described by Heeringa et al.14 (p. 107-108)  
 
We draw B replicate samples from the primary sample by selecting 𝑚ℎ = 𝑛ℎ − 1 PSUs from 
each stratum ℎ, with replacement, where 𝑛ℎ  is the number of PSUs that were sampled in 
stratum ℎ. Within each replicate sample b, bootstrap weights (𝑤ℎ𝑖
(𝑏)
) are calculated for each 
individual 𝑖  in stratum ℎ, based on the number of times their PSU was selected within b 







∗ 𝑟(𝑏)   (Equation 8) 
𝑊ℎ𝑒𝑟𝑒 𝑟(𝑏) 𝑖𝑠 𝑡ℎ𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑖𝑚𝑒𝑠 𝑡ℎ𝑒 𝑃𝑆𝑈𝑎𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝑢𝑛𝑖𝑡 𝑖 𝑖𝑠 𝑠𝑒𝑙𝑒𝑐𝑡𝑒𝑑 𝑖𝑛 𝑟𝑒𝑝𝑙𝑖𝑐𝑎𝑡𝑒 𝑏. 
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Subsequently, we calculate weighted population estimates ( ?̂?𝑏)  for the proportion of 
individuals with positive serology tests, for each replicate sample b.  
 
Next, we account for variation in the sensitivity and specificity estimates. Assume that 
sensitivity and specificity were estimated based on lab tests of samples of sizes  𝑡1 and 𝑡2, 
respectively. We take random draws from two independent binomial distributions to estimate 
sensitivity and specificity for each bootstrap sample. That is, we let 𝑋1~𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑡1, 𝑠𝑒𝑛𝑠) 
and 𝑋2~𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑡2, 𝑠𝑝𝑒𝑐)  and estimate sensitivity ( 𝑠𝑒𝑛𝑠
𝑏 = 𝑥1/𝑡1)  and specificity 
(𝑠𝑝𝑒𝑐𝑏 = 𝑥2/𝑡2).  We then estimate seroprevalence for each bootstrap sample using the 
Rogan-Gladen estimator ( ?̂?′𝑏 ), where sensitivity and specificity are the bootstrap-specific 
values (𝑠𝑒𝑛𝑠𝑏 and 𝑠𝑝𝑒𝑐𝑏). This process accounts for variation both in selection of the sample 
and in estimation of the sensitivity and specificity of the diagnostic test.   
 
This process results in 𝐵 estimates of ?̂?′𝑏, one for each iteration of the bootstrap. We then use 
the distribution of all B estimates to calculate confidence interval endpoints at the 
𝛼
2







Simulation Study  
 
A simulation study was conducted to assess the performance, measured by empirical bias, 95% CI 
coverage, and CI width, of the estimators described in Stage 3 of the Methods section. The 
simulation was modeled after the Chatham County COVID-19 Cohort (C4) study, which is based 
on a stratified, 2-stage cluster design aiming to recruit Chatham County residents from 300 
households across 141 sampled census blocks, which are the PSUs.16 Additional details about the 
C4 study are provided in the Application section below.  
 
The following simulation was conducted in SAS Studio 3.8 with 500 iterations. 
 
Generate population data. First, the true infection status and diagnostic test status were 
generated for all individuals in the target population, as follows. Census data were used to 
estimate the number of households in Chatham County within each PSU. As in the C4 study, 
PSUs were stratified into three income strata. The base probability of infection for households 
in each income stratum 1 through 3 was assumed to be 0.15, 0.10, or 0.05, respectively. A 
cluster effect was generated by a random uniform variable with range ±0.5%. The true 
sensitivity value for the iteration was defined as 𝑆1/145, where 𝑆1~𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙(145, 0.897) 
given that 0.897 was the lab-reported sensitivity for the serology assay used in the C4 study, 
based on 145 known positive samples. The true specificity value for the iteration was similarly 
derived ( 𝑠𝑝𝑒𝑐(𝑙𝑎𝑏) = 0.993, 𝑛 = 274 ). Within each household in the population, a true 
infection status was generated for the sampled individual based on the combined base risk and 
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cluster effect; the true value of 𝑝 was thus determined for the population. Additionally, a 
diagnostic test status was generated for each individual based on the sensitivity and specificity 
for the iteration. Across the 500 simulated samples, the mean value of 𝑝 was 0.0907 with a 
range of 0.0857 to 0.0957. 
 
Determine sample estimate. A sample of PSUs was selected from each stratum (n1 = 51, n2 
= 51, n3 = 60) with probability of selection proportional to the number of households in each 
PSU. Up to 6 households were randomly selected without replacement from each PSU, as in 
the study design. The Rogen-Gladen corrected sample estimate ?̂?′ was calculated from the 
ratio estimate for the mean diagnostic test status in the sample, ?̂?. 
 
Construct confidence interval. 1000 bootstrap samples were selected with replacement from 
the sample with 𝑚ℎ = 𝑛ℎ − 1  (i.e., with m1 = 50, m2 = 50, m3 = 59) and ?̂?′
𝑏 was calculated 
for each bootstrap sample as described in the methods above. The CI was defined as the 2.5 
and 97.5 quantiles of the distribution of 1000 ?̂?′𝑏 estimates (corresponding to a 95% CI). 
 
The simulation study resulted in 500 values of ?̂?′  and corresponding confidence intervals. 
Empirical bias (?̂?′ −  𝑝) remained low across the 500 iterations, with a mean of 0.0008 and range 
from -0.0411 to 0.0348. The distribution of empirical bias, shown in Figure 1, is centered close to 
zero. The CI width, determined by the mean width from all iterations, was 0.0487. Empirical 
coverage, measured as the proportion of CIs that contained the corresponding true value 𝑝, was 
95.6%, just above the target value of 95%.  
 
 
Figure 1. Histogram and boxplot for empirical bias (500 simulations; mean, 0.0008; 
range, -0.0411–0.0348). 
 
In sum, the simulation study demonstrates low empirical bias and appropriate CI coverage for the 
methods proposed in Stage 3 when sensitivity and specificity are estimated within the context of a 




The Chatham County COVID-19 Cohort (C4) study is a longitudinal, prospective, population-
based study aimed at estimating the prevalence of SARS-CoV-2 infection in central North 
Carolina. Study participants are Chatham County residents age 18 or older who were selected 
through a stratified, 2-stage cluster design targeting a total enrollment of 300 participants across 
141 randomly selected census blocks. Census blocks were stratified across 3 income brackets and 
selected using probability proportional to size with replacement (PPS-WR) sampling, with the 
number of occupied households in each block serving as the measure of size. Individuals from 
approximately 6 households were sampled per census block. Households in census blocks with 
more concentrated Hispanic/Latino and/or Black/African American populations (based on 2010 
Census data) were oversampled to facilitate seroprevalence estimation by race/ethnicity.16 
 
For the seroprevalence study, serum samples are being collected from participants once a month 
via venous blood draws during in-person clinic visits or using a Tasso serum self-collection device 
at home. Serum samples are tested with ELISA, using the recombinant spike protein antigen to 
detect total SARS-CoV-2 Ig in plasma17 (sensitivity = 0.897, specificity = 0.993). This assay 
detects seropositivity due to either prior SARS-CoV-2 infection or vaccination. 
 
The proposed method described in Stage 3 of the Methods section was applied (B = 1000) to 
preliminary study data collected through March 9, 2021. The most recent serology result for each 
of the 118 participants recruited to date from 74 census blocks was analyzed using base 
(unadjusted) sampling weights. The resulting unadjusted and sensitivity-specificity adjusted 
seroprevalence estimates, along with their corresponding CIs, are shown in Table 1. Both estimates 
were noticeably greater than initially expected due to the beginning of vaccination amongst the 
cohort. The upwards adjustment of the estimate and associated confidence interval were consistent 
with each other. Without using the Rogan-Gladen estimator and the bootstrap CI, seroprevalence 
would be underestimated due to the assay’s very high specificity but lower sensitivity, which has 
the tendency to produce more false negative results than false positive results. The bootstrap CI 
width was greater than the unadjusted CI width. The wide CI widths could be due to the 
preliminary data still representing only about half of the target sample size. 
 
 
Table 1. Adjusted and unadjusted seroprevalance estimates and CI widths based on C4 study data collected through 
March 9, 2021 (n = 118).  
 Seroprevalence Estimate (%) CI Width (%) 
Adjusted – Bootstrap CI 32.0 (20.8, 44.9) 24.1 






Conditions of the COVID-19 pandemic have emphasized the need for accurate seroprevalence 
estimators to monitor virus transmission and mortality rates. Furthermore, these estimators should 
account for measurement error introduced by diagnostic tests and be compatible with probability-
based survey sampling study designs, which are often used to improve feasibility of data collection 
and generalizability of results to the target population. The Rogan-Gladen estimator, paired with a 
CI generated through the proposed two-stage non-parametric bootstrap method, will allow for 
seroprevalence estimation in complex survey designs while adjusting for sensitivity-specificity of 
diagnostic tests as well as minimizing CI width and coverage issues that are common for small 
proportions. Simulations demonstrated low empirical bias (mean, 0.0008; range, -0.0411–0.0348) 
and nominal CI coverage (95.6%) when diagnostic test sensitivity and specificity are estimated. 
Furthermore, the methods accounted for the diagnostic test’s lower sensitivity and higher 
specificity when applied to preliminary data from the C4 study. 
 
There are limitations associated with the proposed methods. The bootstrap technique is 
computationally intensive, especially when a large number of bootstrap samples is desired. 
Additionally, the methods require knowledge of diagnostic test sensitivity-specificity estimates as 
well as the related validation study sample sizes. Despite these limitations, the proposed methods 
provide a promising approach towards confidence interval construction for seroprevalence 
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